FDA Halts Fulcrum Trial, the Latest Setback in a Week of Sickle Cell Stumbles
A Fulcrum Therapeutics clinical trial testing a potential sickle cell disease drug has been paused by the FDA. With the clinical hold on the early-stage study, Fulcrum becomes the fourth company with a stalled…
Continue Reading
